A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation

References

• Substance Abuse and Mental Health Services Administration. 2019. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/. Accessed February 3, 2020.
   Google Scholar
• Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry. 2017;74(9):911–923.
   PubMed Web of Science ®Google Scholar
• Barocas JA, White LF, Wang J, et al. Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: a capture-recapture analysis. Am J Public Health. 2018;108(12):1675–1681.
   PubMed Web of Science ®Google Scholar
• Weiss AJ, Elixhauser A, Barrett ML, Steiner CA, Bailey MK, O’Malley L. Opioid-Related Inpatient Stays and Emergency Department Visits by State, 2009–2014. HCUP Statistical Brief #219. Rockville, MD: Agency for Healthcare Research and Quality; 2016. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb219-Opioid-Hospital-Stays-ED-Visits-by-State.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. Annual Surveillance Report of Drug-Related Risks and Outcomes — United States, 2017. Surveillance Special Report 1. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. https://www.cdc.gov/drugoverdose/pdf/pubs/2017cdc-drug-surveillance-report.pdf. Published August 31, 2017. Accessed November 20, 2017.
   Google Scholar
• Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug overdose deaths involving cocaine and psychostimulants with abuse potential – United States, 2003–2017. Morb Mortal Wkly Rep. 2019;17(68):388–395.
   Google Scholar
• LaBelle CT, Han SC, Bergeron A, Samet JH. Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abuse Treat. 2016;60:6–13.
   PubMed Web of Science ®Google Scholar
• Shanahan CW, Beers D, Alford DP, Brigandi E, Samet JH. A transitional opioid program to engage hospitalized drug users. J Gen Intern Med. 2010;25(8):803–808.
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–1376.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–1644.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Metlay JP, Chang Y, Herman GE, Rigotti NA. Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity. J Gen Intern Med. 2017;32(8):909–916.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rigotti NA, Chang Y, et al. Effect of integrating substance use disorder treatment into primary care on inpatient and emergency department utilization. J Gen Intern Med. 2019;34(6):871–877. doi:https://doi.org/10.1007/s11606-018-4807-x
   PubMed Web of Science ®Google Scholar
• Englander H, Dobbertin K, Lind BK, et al. Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis. J Gen Intern Med. 2019;34(12):2796–2803. doi:https://doi.org/10.1007/s11606-019-05251-9
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74.e11–74.e7.4E17. doi:https://doi.org/10.1016/j.amjmed.2012.07.005
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2(2):CD002207.
   Google Scholar
• Larochelle MR, Bernstein R, Bernson D, et al. Touchpoints – opportunities to predict and prevent opioid overdose: a cohort study. Drug Alcohol Depend. 2019;204:107537.
   PubMed Web of Science ®Google Scholar
• The Massachusetts Board of Substance Abuse Counselor Certification. CARC Information and Requirements. Available online at https://www.mbsacc.com/carc. Accessed July 14, 2020.
   Google Scholar
• Oliva EM, Trafton JA, Harris AH, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39(2):103–107.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017;171(8):747–755. doi:https://doi.org/10.1001/jamapediatrics.2017.0745
   PubMed Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–981. doi:https://doi.org/10.1001/jamapsychiatry.2019.0876
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145.
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Jaffe JH, Schwartz RP, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285–291.
   PubMed Web of Science ®Google Scholar